RaQualia Pharma Inc.
4579 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 名古屋市中村区名駅南一丁目２１番１９号
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
RaQualia Pharma Inc. is a Japanese biopharmaceutical company focused on the discovery, development, and commercialization of innovative drug candidates for various therapeutic areas. Established with a commitment to enhancing patient care, RaQualia harnesses advanced scientific research and cutting-edge technologies to address unmet medical needs. The company's portfolio includes a range of proprietary compounds aimed at treating conditions in areas such as pain management and gastrointestinal disorders. With a dedication to collaboration and strategic partnerships, RaQualia seeks to expedite the drug development process and bring effective therapies to market, contributing to the global healthcare landscape.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-04-18 08:30 |
Inside Information Statement
臨時報告書
|
Japanese | 21.1 KB | |
| 2025-03-31 09:01 |
Regulatory News Service
訂正有価証券届出書（参照方式）
|
Japanese | 155.4 KB | |
| 2025-03-31 08:31 |
Regulatory News Service
訂正確認書
|
Japanese | 8.2 KB | |
| 2025-03-31 08:30 |
Regulatory News Service
訂正有価証券報告書－第17期(2024/01/01－2024/12/31)
|
Japanese | 811.9 KB | |
| 2025-03-26 08:05 |
Regulatory News Service
訂正有価証券届出書（参照方式）
|
Japanese | 158.4 KB | |
| 2025-03-26 07:52 |
Inside Information Statement
臨時報告書
|
Japanese | 22.7 KB | |
| 2025-03-26 07:51 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2025-03-26 07:50 |
Internal Control over Financial Reporting
内部統制報告書－第17期(2024/01/01－2024/12/31)
|
Japanese | 23.1 KB | |
| 2025-03-26 07:49 |
Annual Report
有価証券報告書－第17期(2024/01/01－2024/12/31)
|
Japanese | 1.4 MB | |
| 2025-03-21 07:30 |
Prospectus
有価証券届出書（参照方式）
|
Japanese | 282.6 KB | |
| 2024-12-13 08:00 |
Inside Information Statement
臨時報告書
|
Japanese | 20.7 KB | |
| 2024-10-01 09:04 |
Regulatory News Service
訂正臨時報告書
|
Japanese | 35.8 KB | |
| 2024-09-13 08:31 |
Inside Information Statement
臨時報告書
|
Japanese | 37.9 KB | |
| 2024-08-14 08:47 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2024-08-14 08:46 |
Interim Report
半期報告書－第17期(2024/01/01－2024/12/31)
|
Japanese | 234.4 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
D.Western Therapeutics Institute, Inc. | Japan | 4576 | |
|
EARNZ PLC | United Kingdom | EARN | |
|
Eevia Health Plc | Finland | EEVIA | |
|
Egetis Therapeutics | Sweden | EGTX | |
|
EIKEN CHEMICAL CO.,LTD. | Japan | 4549 | |
|
Eisai Co., Ltd. | Japan | 4523 | |
|
ELARIS AG | Germany | ELS | |
|
Enervit | Italy | ENV | |
|
Enorama Pharma AB | Sweden | ERMA | |
|
Enzymatica AB | Sweden | ENZY |